Loading…
← CockpitCompetitor Analysis › 4521.T Kaken Pharmaceutical Co., Ltd.Open in the cockpit ↗

Kaken Pharmaceutical Co., Ltd.4521.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum neutral 46
Mkt cap
$860M
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$3.06M
20-day average traded
Fwd P/E
21.4×
forward earnings
ROIC−WACC
+1.4 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
78 days
4 Feb 2027
Close · JPY¥3,815
1D-0.7%
1W+0.7%
1M+0.1%
3M-5.0%
6M-8.1%
YTD-5.0%
1Y+3.4%
ATR %1.7%
52w lowhigh14.2% off high

What Kaken Pharmaceutical does

Employees: 1,114

Kaken Pharmaceutical at a glance

Size Kaken Pharmaceutical (4521.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $860M, the 810th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,815 on 18 Nov 2026.

Performance Over six months the shares fell 8.1%, against -22.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 19 in its peer set.

Growth Revenue grew 5.4% over the last twelve months (peer median +1.7%); the operating margin is 10.5% (peer median 1.4%).

Valuation It trades at 21.4× forward earnings against a peer median of 28.1× (4th cheapest of 8).

Capital Return on invested capital runs 1.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 20264521.T 92Peer median 77
Six months, rebased to 100: Kaken Pharmaceutical against the median of its 20 peers (local-currency closes).

Kaken Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥86.5B¥76.9B¥94.0B¥72.0B¥73.0B
Revenue growth—-18%+31%-1%—
Gross profit¥49.2B¥39.2B¥58.3B¥38.2B¥39.3B
EBITDA¥13.0B¥2.43B¥23.6B¥12.3B¥10.6B
Net income¥9.15B¥2.14B¥13.9B¥8.03B¥5.44B
Free cash flown/a-¥14.1B¥25.6B¥716M¥7.27B
Capital expendituren/a¥5.72B¥4.66B¥2.17B¥2.21B
Total debt¥4.55B¥3.94B¥3.96B¥3.85B¥3.85B

Quarterly statements and history in the cockpit →

Kaken Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%CRVS069620086450600771006120688176PHARMSANOFICONR688621300267000597AKTS000813603229002082688553259560784521.T6-month return →1-month return →
Up and to the right = strong over both horizons. Kaken Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%10×20×30×40×069620086450600771PHARMSANOFICONR68862160784521.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kaken Pharmaceutical is the large dot.

Kaken Pharmaceutical competitors and peer comparison

How Kaken Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kaken Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4521.TPeer medianRank in peer set
1-month return+0.1%-10.5%4th highest of 21
6-month return-8.1%-22.8%6th highest of 19
Distance from 52-week high-14.2%-42.6%2nd highest of 21
Revenue growth (TTM)+5.4%+1.7%9th highest of 19
Operating margin10.5%1.4%4th highest of 19
Forward P/E21.4×28.1×4th cheapest of 8
ROIC minus cost of capital+1.4 pp-3.5 pp6th highest of 16
EV / EBITDA6.3×9.9×cheapest of 7
Net debt / EBITDA-4.2×0.7×least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%21.4×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%9.0×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%14.0×-4.2%+10.6%
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%38.3×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%n/an/an/a
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%n/an/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%34.9×2.4%+12.4%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%28.1×17.7%+22.7%
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%29.0×n/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%

Questions

Which companies are Kaken Pharmaceutical's closest peers?
The cockpit's peer set: City Therapeutics (CTY), Corvus Pharmaceuticals (CRVS), Daewoong Pharm (069620.KS), DongKook Pharmaceutical (086450.KS), GuangYuYuan Chinese Herbal Medicine (600771.SS), SK Discovery (006120.KS), Jiangsu Yahong Meditech (688176.SS), Pharming (PHARM.AS).
Is Kaken Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 21.4× against a peer median of 28.1×, 4th cheapest of 8 in its peer set.
How has Kaken Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -8.1% against -22.8% for the median peer; over one year +3.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.